Jim Cramer's Top Stock Picks: CRL TSLA EOG

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's Mad Money on CNBC:

CRL Chart
CRL
data by YCharts

Charles River Labs (CRL): The biotech group continues to flourish, said Cramer, and Charles River Labs is a solid way to play the trend.

TSLA Chart
TSLA
data by YCharts

Tesla Motors (TSLA): No doubt Tesla shares are trading on emotion, said Cramer, but the company's promise might just be realized some day.

EOG Chart
EOG
data by YCharts

EOG Resources (EOG): Cramer said he's still a fan of EOG Resources for both retirement and discretionary portfolios.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

If you liked this article you might like

GoPro, Alteryx, Charles River Labs, Mallinckrodt: 'Mad Money' Lightning Round

GoPro, Alteryx, Charles River Labs, Mallinckrodt: 'Mad Money' Lightning Round

Don't Get Caught on the Wrong Side: Cramer's 'Mad Money' Recap (Wed 11/15/17)

Don't Get Caught on the Wrong Side: Cramer's 'Mad Money' Recap (Wed 11/15/17)

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Parexel Is Discovering the Drugs of the Future

Parexel Is Discovering the Drugs of the Future